• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Challenges with Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice.

作者信息

Jadvar Hossein, Iravani Amir, Bodei Lisa, Calais Jeremie

机构信息

Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California;

Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington.

出版信息

J Nucl Med. 2024 Dec 3;65(12):1851-1854. doi: 10.2967/jnumed.124.268023.

DOI:10.2967/jnumed.124.268023
PMID:39299786
Abstract
摘要

相似文献

1
Challenges with Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice.镥-PSMA-617放射性药物治疗在临床实践中的挑战
J Nucl Med. 2024 Dec 3;65(12):1851-1854. doi: 10.2967/jnumed.124.268023.
2
Preclinical Evaluation of Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy.用于前列腺癌的放射性药物Lu-rhPSMA-10.1的临床前评估：生物分布与治疗效果
J Nucl Med. 2025 Apr 1;66(4):599-604. doi: 10.2967/jnumed.124.268508.
3
RECIP 1.0 Predicts Progression-Free Survival After [Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.RECIP 1.0 预测转移性去势抵抗性前列腺癌患者接受 [Lu]Lu-PSMA 放射性药物治疗后的无进展生存期。
J Nucl Med. 2024 Jun 3;65(6):917-922. doi: 10.2967/jnumed.123.267234.
4
Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to Lu-PSMA therapy of prostate cancer.实体瘤中放射性药物转运的时空建模：在前列腺癌镥-PSMA治疗中的应用。
Comput Methods Programs Biomed. 2024 Mar;245:108004. doi: 10.1016/j.cmpb.2023.108004. Epub 2024 Jan 1.
5
Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.最佳患者护理实践用于给予 PSMA 靶向放射性药物治疗。
J Nucl Med. 2024 Nov 1;65(11):1666-1671. doi: 10.2967/jnumed.124.268363.
6
Estimation of relative biological effectiveness of Ac compared to Lu during [Ac]Ac-PSMA and [Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS.使用TOPAS/TOPAS-nBio/MEDRAS评估[锕-225]锕-PSMA和[镥-177]镥-PSMA放射性药物治疗期间锕与镥的相对生物有效性。
EJNMMI Phys. 2023 Sep 11;10(1):53. doi: 10.1186/s40658-023-00567-2.
7
Lesion Dosimetry for [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer.[Lu]Lu-PSMA-617 放射性药物治疗联合立体定向体部放射治疗寡转移去势敏感性前列腺癌患者的病灶剂量学
J Nucl Med. 2023 Nov;64(11):1779-1787. doi: 10.2967/jnumed.123.265763. Epub 2023 Aug 31.
8
Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.探索外照射放疗与[镥]镥-PSMA-617靶向放射性配体疗法联合用于前列腺癌的作用——从实验室到临床应用
Theranostics. 2024 Apr 8;14(6):2560-2572. doi: 10.7150/thno.93249. eCollection 2024.
9
Biodistribution and dosimetry of [Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer.[镥]Lu-SibuDAB在转移性去势抵抗性前列腺癌患者中的生物分布与剂量测定
Eur J Nucl Med Mol Imaging. 2025 Feb 3. doi: 10.1007/s00259-025-07102-8.
10
Dosimetry of [Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.[镥 Lu]Lu-PSMA 靶向放射性药物治疗前列腺癌的剂量学：一项比较系统的综述和荟萃分析。
J Nucl Med. 2024 Aug 1;65(8):1264-1271. doi: 10.2967/jnumed.124.267452.

引用本文的文献

1
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy.PSMA正电子发射断层显像在接受放射性配体治疗的转移性去势抵抗性前列腺癌患者管理中的应用
Target Oncol. 2025 May 26. doi: 10.1007/s11523-025-01151-7.